NCT05355987Completed
Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma
Impact of Point in Time of Introducing Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
Multiple myeloma is the second most frequent hematologic malignancy, which incidence augmented between 1995 and 2018, with an annual mean variation of +0.6% to 1.1%. Although treatment improved in the last years, the patients' prognostic is associated with cytogenetic abnormalities. Oncological supportive care provides patients with a global perspective, in addition to specific medical treatment adapted to pathology and patient profile. It contributes to the improvement of quality of life of patients, throughout their care pathway regarding physical, psychological and social aspects, according to their specific needs as well as their caregivers'. The aim of this study is to evaluate the quality of life at 6 months after multiple myeloma diagnosis in outpatients receiving paramedical consultations in oncological supportive care from the diagnosis versus outpatients receiving paramedical consultations in oncological supportive care after 6 months after diagnosis.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 26 Apr 2022
- Start date
- 3 Jun 2022
- Primary completion date
- 2 Jun 2025
- Lead sponsor
- Centre Henri Becquerel
- Diseases
- Multiple myeloma
- NCT number
- NCT05355987
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 3 Jun 2022 to the primary completion date, 2 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient recently diagnosed with multiple myeloma not eligible to autologous blood stem-cell transplantation, before starting therapy in day hospital
Other illness
- History of psychological or sensorial disorder or anomaly that can prevent the patient from understanding the conditions for study participation
Age
- Age superior to 18 years old
Other
- Inclusion Criteria:
- Patient coming regularly to Centre Henri Becquerel for treatment and follow up for multiple myeloma
- Informed consent form signed
- Patient with urgent need of treatment after multiple myeloma diagnosis with urgent and absolute need of oncological supportive care immediately after diagnosis
- Patient deprived of liberty, under judicial supervision, under guardianship or trusteeship
Who the study is looking for
- Age superior to 18 years old
- Patient recently diagnosed with multiple myeloma not eligible to autologous blood stem-cell transplantation, before starting therapy in day hospital
- Patient coming regularly to Centre Henri Becquerel for treatment and follow up for multiple myeloma
- Informed consent form signed
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Henri Becquerel Coordinator of this site? Confirm its status | Rouen | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.